NCT01031719已完成3 期
A Phase III, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Vaccine Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Invasive Solid Tumors
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 3
- 主要终点
- The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with invasive solid tumors
研究概览
简要总结
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of A(H1N1) inactivated influenza virus vaccine in subjects with Solid Invasive Tumors and to compare safety and immunogenicity data with a contemporaneously enrolled control group of age-comparable, healthy subjects.
Because certain individuals may be hypo-responsive to influenza vaccination, additional studies with high-risk groups are warranted in order to determine the optimal vaccine formulation and dosing schedule for prevention of novel H1N1 virus infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For Invasive Solid Tumor Subjects:
- •Subjects between 2 and 70 years of age (inclusive)
- •Any sex or ethnicity
- •Confirmed diagnosis of Invasive Solid Tumor or hematological malignancies in complete remission for at least 3 months and not more than 18 months after the last neo-adjuvant and/or adjuvant chemotherapy cycle according to investigators assessment and the subjects medical records
- •Previous use of neo-adjuvant and/or adjuvant chemotherapy for the treatment on an invasive solid tumor
- •Life expectancy of at least 12 months
- •Karnofsky Performance Scale > 40%
- •Childbearing potential women must be willing to use an acceptable contraceptive method. Acceptable contraceptive methods are defined as one or more of the following:
- •Hormone contraceptive (such as oral, injectable, transdermal patch, subcutaneous implant, cervical ring)
- •Barrier (condom with spermicide or diaphragm with spermicide) at each intercourse and during the whole intercourse
- •Intra-uterine device (IUD)
- •Monogamous relation with vasectomized partner (must have been vasectomized at least six months before the volunteer entered the study).
- •Subjects capable of following all the study procedures and available for all visits scheduled to the investigation site
- •Subjects capable of understanding the nature and risk of the study proposed and sign the consent form
- •In case of children and adolescents (below 18 years of age): Subjects capable of understanding the nature of the study and whose legal guardian understands the nature and risk of the study proposed and signs the consent form
- •The study subjects may have other underlying chronic diseases that do not involve immunosuppression (e.g. osteoarticular diseases, cardiorespiratory diseases, metabolic diseases, stable, non progressive, non-severe neurologic disorders without cognitive impairment, ophthalmologic diseases, etc.), but their symptoms/signs must be under control through medical follow-ups and drug therapy
- •For Healthy Subjects:
- •Subjects between 2 and 70 years of age (inclusive)
- •Any sex and ethnicity
- •Subjects with good health as determined by medical history, physical evaluation, and investigator's clinical opinion
- •Childbearing potential women must be willing to use an acceptable contraceptive method. Acceptable contraceptive methods are defined as one or more of the following:
- •Hormone contraceptive (such as oral, injectable, transdermal patch, subcutaneous implant, cervical ring)
- •Barrier (condom with spermicide or diaphragm with spermicide) at each intercourse and during the whole sexual intercourse
- •Intra-uterine device (IUD)
- •Monogamous relation with vasectomized partner (must have been vasectomized for at least six months before the volunteer entered the study).
- •Subjects capable of respecting all the study procedures and available for all the visits scheduled at the investigation site
- •Subjects capable of understanding the nature and risk of the study proposed and sign the consent form
- •In case of children and adolescents (below 18 years of age): Subjects capable of understanding the nature of the study and whose legal guardian understands the nature and risk of the study proposed and signs the consent form
排除标准
- •For Invasive Solid Tumor Subjects:
- •Previous laboratory confirmed diagnosis of an infection by the novel H1N1 virus
- •Administration of other vaccine against the novel H1N1 virus within 3 months prior to inclusion in the study
- •Any recent vaccine given within the last 21 days (inclusive)
- •History of allergic reaction to an influenza vaccine in the past, or a current or previous occurrence of allergy to egg or egg protein, kanamycin, and neomycin sulfate
- •Acute febrile disease (vaccination may be delayed up to 3 days after the resolution of the symptoms)
- •Presence of other diseases, not related to cancer with confirmed immunosuppression
- •Chemotherapy, biologic therapy or radiation within 3 months prior to inclusion in the study
- •History of chronic hepatic or renal disease
- •History of cognitive disorders
- •History of progressive or severe neurological disorders, including Guillain-Barré Syndrome
- •Pregnancy or breast-feeding
- •Use of immunomodulatory therapy, including cyclosporin, interleukins, and interferons, within 3 months prior to inclusion in the study
- •Receipt of parenteral immunoglobulin, hemotherapy, and/or plasma derivatives within 3 months prior to inclusion in the study
- •Receipt of any investigational product within 12 months prior to inclusion in the study
- •For Healthy Subjects:
- •Previous laboratory confirmed diagnosis of an infection by the new virus H1N1
- •Receipt of another vaccine against the new virus H1N1 within 3 months prior to inclusion in the study
- •Any recent vaccine given within the last 21 days (inclusive)
- •History of allergic reaction to influenza vaccine in the past, or a current or previous allergy to egg or egg protein, kanamycin, and neomycin sulfate;
- •Acute febrile disease (the vaccination may be delayed up to 3 days after symptoms resolution)
- •Pregnancy or breast-feeding
- •Receipt of parenteral immunoglobulin, hemotherapy, and/or plasma derivatives within 3 months prior to inclusion in the study;
- •Receipt of any investigational product within 12 months prior to inclusion in the study
结局指标
主要结局
The primary objective of this study is to determine the optimal influenza vaccination strategy in patients with invasive solid tumors
时间窗: 3 months
次要结局
- Assess whether the adjuvanted vaccine offers a meaningful benefit in relation to the non-adjuvanted vaccine in this at-risk population(3 months)
- Assess whether two doses of either study vaccine will provide meaningful benefit in comparison to one dose(3 months)
- Assess the persistence of antibody levels in the two vaccine groups(3 months)
- Gain further insight into the safety of the adjuvanted and non-adjuvanted H1N1 vaccines in this high-risk patient population(3 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes MellitusH1N1 Influenza VirusChronic Pulmonary DiseaseChronic Heart DiseaseDiabetes MellitusNCT01032395Chiltern Pesquisa Clinica Ltda342
已完成
3 期
Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 InfectionH1N1 Influenza VirusHuman Immunodeficiency Virus Type 1 (HIV-1) InfectionNCT01032408Chiltern Pesquisa Clinica Ltda154
进行中（未招募）
3 期
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490
已完成
3 期
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell CancerPrimary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1NCT04394975Shanghai Junshi Bioscience Co., Ltd.421
招募中
3 期
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerOvarian CancerNCT06394492Suzhou Suncadia Biopharmaceuticals Co., Ltd.440